Other formats:
BibTeX
LaTeX
RIS
@misc{2327489, author = {Demlová, Regina and Grodová, Karolína and Maláska, Jan}, address = {Brno}, edition = {NA}, keywords = {REMED; COVID-19; dexamethason; annual safety report; development safety update report; DSUR}, language = {eng}, location = {Brno}, publisher = {MU LF/MŠMT/FN BRNO}, title = {DEVELOPMENT SAFETY UPDATE REPORT REMED 19. 1. 2023 – 23. 2. 2023}, url = {https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005887-70}, year = {2023} }
TY - GEN ID - 2327489 AU - Demlová, Regina - Grodová, Karolína - Maláska, Jan PY - 2023 TI - DEVELOPMENT SAFETY UPDATE REPORT REMED 19. 1. 2023 – 23. 2. 2023 VL - NA PB - MU LF/MŠMT/FN BRNO CY - Brno KW - REMED KW - COVID-19 KW - dexamethason KW - annual safety report KW - development safety update report KW - DSUR UR - https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005887-70 N2 - REMED is national, multicentre clinical trial carried out by the University Hospital Brno in cooperation with RI CZECRIN. The primary objective of the study is to test the hypothesis that administration of dexamethasone 20 mg daily is more effective with COVID-19 compared to a daily dose of dexamethasone 6 mg in adult patients with moderate or severe ARDS. During year 2021 was eight newsletters prepared and sent to clinical sites. ER -
DEMLOVÁ, Regina, Karolína GRODOVÁ and Jan MALÁSKA. \textit{DEVELOPMENT SAFETY UPDATE REPORT REMED 19. 1. 2023 – 23. 2. 2023}. NA. Brno: MU LF/MŠMT/FN BRNO, 2023, 14 pp. NA.
|